207279-31-0

Upstream product

• 55716-28-4 8-methoxy-[1,7]naphthyridin-6-ylamine 
• 207279-29-6 8-methoxy-1,7-naphthyridin-6-yl trifluoromethanesulfonate 
• 5912-34-5 2-cyano-pyridin-3-yl-acetonitrile 
• 14047-29-1 4-carboxyphenylboronic acid 
• 207279-30-9 6-(4-carboxyphenyl)-8-methoxy-1,7-naphthyridine 

Downstream Products

• 426268-06-6 RO-458,2640 
• 207279-12-7 6-(4-carboxyphenyl)-8-(4-benzo[c]furazanyl)-1,7-naphthyridine 

Relevant academic research and scientific papers

Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: A potent and selective phosphodiesterase type 4D inhibitor

The synthesis of a 6,8-disubstituted 1,7-naphthyridine 1 and its characterization as a potent and selective phosphodiesterase type 4D inhibitor (IC50=1.5nM) are described. The compound inhibited TNFα-release from human peripheral blood mononuclear cells and was orally active in a model of adjuvant-induced arthritis in rats.

Naphthyridine derivatives

PCT No. PCT/EP97/05898 Sec. 371 Date Apr. 27, 1999 Sec. 102(e) Date Apr. 27, 1999 PCT Filed Oct. 24, 1997 PCT Pub. No. WO98/18796 PCT Pub. Date May 7, 1998Novel 8-aryl-1,7-naphthyridines, in free or salt form, are PDE IV inhibitors and are thus useful as pharmaceuticals, e.g. for asthma therapy. Preferred compounds include compounds of formulae (I and II) wherein the R groups are as defined. Pharmaceutical compositions comprising the compounds, processes for preparation of the compounds and novel intermediates for use in the processes are disclosed.